Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study
暂无分享,去创建一个
P. Macfarlane | I. Ford | C. Packard | N. Sattar | J. Shepherd | S. Cobbe | C. Isles | A. Gaw | O. Scherbakova | D. O’Reilly | S. Haffner
[1] L. Groop,et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.
[2] S. Haffner,et al. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans--a 7-year prospective study. , 1997, Obesity research.
[3] P. Ridker. Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. , 2002, Circulation.
[4] P W Macfarlane,et al. Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.
[5] P. Nihoyannopoulos,et al. Central role of echocardiography in the diagnosis and assessment of heart failure. British Society of Echocardiography. , 1998, Heart.
[6] S. Haffner,et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.
[7] Gary L Myers,et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.
[8] Petros Nihoyannopoulos,et al. Joint British recommendations on prevention of coronary heart disease in clinical practice , 1998, Heart.
[9] G. Lowe,et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.
[10] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[11] J. Manson,et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.
[12] P. Macfarlane,et al. SCREENING EXPERIENCE AND BASE-LINE CHARACTERISTICS IN THE WEST OF SCOTLAND CORONARY PREVENTION STUDY , 1995 .
[13] J. Pankow,et al. Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. , 2001, Obesity research.
[14] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[15] M. Laakso,et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.
[16] References , 1971 .
[17] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[18] N. Sattar,et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. , 2002, Diabetes.
[19] P. Zimmet,et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[20] C. Ballantyne,et al. Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S , 2001, Circulation.
[21] W. Dietz,et al. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.
[22] C. Morrison,et al. Waist circumference as a measure for indicating need for weight management , 1995, BMJ.
[23] P. Macfarlane,et al. The prognostic value of the electrocardiogram in the west of Scotland coronary prevention study , 2002 .
[24] J. Buring,et al. Abdominal and total adiposity and risk of coronary heart disease in men , 2001, International Journal of Obesity.
[25] Nancy R Cook,et al. C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.
[26] P. Ridker. Role of inflammatory biomarkers in prediction of coronary heart disease , 2001, The Lancet.
[27] Jukka T Salonen,et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.
[28] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.